Apellis PharmaceuticalsAPLS
APLS
About: Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
Employees: 710
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
212% more call options, than puts
Call options by funds: $104M | Put options by funds: $33.5M
37% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 71
16% more capital invested
Capital invested by funds: $3.49B [Q3] → $4.04B (+$553M) [Q4]
2.48% more ownership
Funds ownership: 99.41% [Q3] → 101.9% (+2.48%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 6 [Q3] → 6 (+0) [Q4]
2% less first-time investments, than exits
New positions opened: 60 | Existing positions closed: 61
2% less funds holding
Funds holding: 261 [Q3] → 257 (-4) [Q4]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$25
10%
upside
Avg. target
$39
74%
upside
High target
$57
151%
upside
5 analyst ratings
2 positive
40%
3 neutral
60%
0 negative
0%
JP Morgan Anupam Rama 25% 1-year accuracy 15 / 61 met price target | 138%upside $54 | Overweight Maintained | 4 Mar 2025 |
RBC Capital Luca Issi 22% 1-year accuracy 12 / 55 met price target | 10%upside $25 | Sector Perform Maintained | 3 Mar 2025 |
Goldman Sachs Salveen Richter 24% 1-year accuracy 4 / 17 met price target | 41%upside $32 | Neutral Maintained | 3 Mar 2025 |
Wedbush Laura Chico 19% 1-year accuracy 10 / 54 met price target | 28%upside $29 | Neutral Maintained | 3 Mar 2025 |
HC Wainwright & Co. Douglas Tsao 23% 1-year accuracy 39 / 171 met price target | 151%upside $57 | Buy Reiterated | 3 Mar 2025 |
Financial journalist opinion
Based on 5 articles about APLS published over the past 30 days
Positive
Benzinga
7 hours ago
FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals
The U.S. Food and Drug Administration (FDA) on Tuesday accepted and granted Priority Review designation to Apellis Pharmaceuticals, Inc.'s APLS supplemental New Drug Application (sNDA) for Empaveli (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).
Neutral
GlobeNewsWire
14 hours ago
Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
PDUFA target action date is July 28, 2025 WALTHAM, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review designation of the supplemental New Drug Application (sNDA) for EMPAVELI® (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), which are severe and rare kidney diseases.
Positive
Seeking Alpha
3 weeks ago
Apellis Pharmaceuticals: A Mixed Bag
Commerical stage Apellis Pharmaceuticals, Inc. recently reported Q4 results that beat expectations. The company posted impressive revenue growth and cost reduction in FY2024. It is a bit of a complicated tale around this mid-cap, but the company looks set to move to profitability with the funding it has on hand.
Positive
Benzinga
3 weeks ago
Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst
Last week, Apellis Pharmaceuticals Inc APLS reported a fourth-quarter earnings loss of 29 cents per share, beating the consensus loss of 37 cents. Sales increased 45.2% to $212.5 million, beating the consensus of $198.35 million.
Positive
Zacks Investment Research
4 weeks ago
Apellis Q4 Loss Narrower Than Expected, Syfovre Sales Drive Revenues
APLS reports better-than-expected fourth-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong sales of Syfovre.
Neutral
Seeking Alpha
1 month ago
Apellis Pharmaceuticals, Inc. (APLS) Q4 2024 Earnings Call Transcript
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q4 2024 Earnings Conference Call February 28, 2025 8:30 AM ET Company Participants Cedric Francois - Co-Founder and CEO Caroline Baumal - Chief Medical Officer David Acheson - EVP, Commercial Tim Sullivan - CFO Meredith Kaya - SVP, IR and Strategic Finance Conference Call Participants Jon Miller - Evercore ISI Tazeen Ahmad - Bank of America Securities Malcolm Kuno - J.P. Morgan Salveen Richter - Goldman Sachs Yigal Nochomovitz - Citigroup Colleen Cusi - Robert W.
Positive
Zacks Investment Research
1 month ago
Compared to Estimates, Apellis Pharmaceuticals (APLS) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for Apellis Pharmaceuticals (APLS) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Negative
Zacks Investment Research
1 month ago
Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Loss, Tops Revenue Estimates
Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.73 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
WALTHAM, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its fourth quarter and full year 2024 financial results and business highlights.
Neutral
GlobeNewsWire
1 month ago
Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference
WALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 10:30 a.m. ET.
Charts implemented using Lightweight Charts™